Schweitzer-Mauduit International, Inc. (“SWM” or “SWM International”) and ConvaTec Ltd. (“ConvaTec”) are pleased to announce that they have entered into a multi-year supply agreement in conjunction with their amicable resolution of pending litigation between the companies. Terms of the settlement and the commercial agreement were not disclosed.
Scapa Healthcare and Synedgen have signed an exclusive worldwide licensing agreement for two novel innovative wound care treatments developed using Synedgen’s proprietary glycochemistry technology platform.
Schweitzer-Mauduit International, Inc. (“SWM” or the “Company”) (NYSE: SWM), announced today that it has finalized its acquisition of Scapa Group Plc, a UK-based innovation, design, and manufacturing solutions provider for healthcare and industrial markets. The newly combined company’s annualized sales are approaching $1.5 billion.
Scapa Healthcare, the trusted strategic partner of choice for the world’s leading companies in advanced wound care, consumer wellness and medical device & fixation, today announced new enhancements at its Hydrocolloid Technology Center in Orangeburg, New York. The company continues to make significant investments to meet growing customer demands for premium medical-grade hydrocolloid adhesive technologies globally. This includes new automated and visual systems for ostomy and consumer products as well as enhancements to high-speed finished packaging, R&D capabilities, unique device identifier (UDI) systems for medical devices, and forecasting & supply chain management tools.
Scapa Healthcare, the trusted strategic partner of choice for the world’s leading companies in advanced wound care, consumer wellness and medical device & fixation, announced today the expansion and enhancement of its Technology Center in Dallas, TX. The company has undertaken significant investment in its topical skin care capabilities to meet increasing customer demands for medicated topical and cosmetic products.
Scapa Healthcare announced the enhancement of its manufacturing and research & development capabilities at its Knoxville, TN center of excellence (COE). The company’s multimillion dollar investments at this facility have created four innovation and product development labs to provide a collaborative space for the development of new technologies and products; contract design and manufacturing operations for over-the-counter (OTC) drugs and pharmaceuticals; and the installation of high speed automated vision systems that enhance process controls to ensure quality and consistency.
Scapa Healthcare, the trusted strategic partner of choice for the world’s leading companies in advanced wound care, consumer wellness and medical device & fixation, today announced expanded medical-grade adhesive coating capabilities in its Windsor, CT and Gargrave, UK facilities. The newly added coating lines increase Scapa’s capacity to custom design and produce polyurethane and polyvinyl chloride foams coated with silicone gels, water-based and solvent-based acrylic adhesives.
Scapa Healthcare provides a full range of sterilisation services including in-house gamma irradiation, microbiology, storage, product stability and global product distribution as well as technical expertise in electron beam and ethylene oxide sterilisation methods.
Throughout the year, the Scapa Healthcare team remained has focused on executing its operational optimization plan and during the pandemic, the team demonstrated determination and adaptability while operating safely at all its global locations to ensure uninterrupted supply chain to its customers.
Scapa Healthcare will be exhibiting its industry leading, innovative and turn-key solutions in Hall 06, Stand 6H48 at MEDICA 2019.
Scapa Healthcare inaugurates its new built-for-purpose medical device manufacturing facility in Knox County, Tennessee today.
The technology also offers high absorption properties which make it ideal for ostomy, wound care and consumer applications where the adhesive comes in contact with fluids. The technology is suitable for users with sensitive skin as the formulation is made of non-animal derived ingredients, colophony and is latex-free.
Scapa Healthcare, a global strategic outsource partner of skin friendly turn-key solutions, announces the availability of Scapa Soft-Pro® Hydrocolloid Acne Patches for the treatment of mild to moderate acne.
Discreet OTC Patches to Conceal & Prevent the Spread of the HSV-1 Virus.
Extensive Toolkit Allows Customers to Bring Innovative Skin-contact Solutions to Market Rapidly
Acquisition Positions Scapa Healthcare as a Leading Manufacturer of Medical Devices
Transaction with Acelity to Expand Scapa Healthcare Advanced Wound Care Capabilities & Services
Formulated with Natural Oils that Support Skin Hydration
Expanded North American Manufacturing Footprint through an Acquisition and New Manufacturing Site
Your Trusted Strategic Outsource Partner